Sanofi lifts guidance as sales rise
Press Hub UCapital
Share:
Sanofi SA reported robust double-digit growth in third-quarter sales and income on Friday, primarily driven by increased vaccine sales, prompting an upgrade to its full-year outlook.
Research and development spending increased by 11% to EUR1.85 billion from EUR1.66 billion, and selling and general expenses rose by 4% to EUR2.68 billion from EUR2.58 billion. CEO Paul Hudson highlighted that the company’s performance was bolstered by flu and Beyfortus vaccine launches and strong growth of 67% for new medicines, along with volume-driven growth from Dupixent. With Dupixent now approved for treating chronic obstructive pulmonary disease (COPD) in the EU, China, and the US, the company aims to reach hundreds of thousands of new patients. Vaccine sales soared 26% at constant exchange rates to EUR3.80 billion, while Pharma and Opella posted sales growth of 13% and 7.9%, reaching EUR8.37 billion and EUR1.27 billion, respectively.
Sanofi lifts guidance as sales rise
The Paris-based pharmaceutical company announced a 12% rise in net income, reaching EUR2.84 billion for the quarter ending September 30, up from EUR2.54 billion in the same period last year. Net sales also grew 12%, amounting to EUR13.44 billion compared to EUR11.96 billion, while the cost of sales increased by 6.4% to EUR4.09 billion from EUR3.84 billion.IFRS earnings per share rose to EUR2.25, up from EUR2.01 year-over-year.
Research and development spending increased by 11% to EUR1.85 billion from EUR1.66 billion, and selling and general expenses rose by 4% to EUR2.68 billion from EUR2.58 billion. CEO Paul Hudson highlighted that the company’s performance was bolstered by flu and Beyfortus vaccine launches and strong growth of 67% for new medicines, along with volume-driven growth from Dupixent. With Dupixent now approved for treating chronic obstructive pulmonary disease (COPD) in the EU, China, and the US, the company aims to reach hundreds of thousands of new patients. Vaccine sales soared 26% at constant exchange rates to EUR3.80 billion, while Pharma and Opella posted sales growth of 13% and 7.9%, reaching EUR8.37 billion and EUR1.27 billion, respectively.